BioCentury
ARTICLE | Clinical News

intravenous CBL0137: Phase I started

August 12, 2013 7:00 AM UTC

Cleveland BioLabs said Incuron LLC JV (Moscow, Russia) began an open-label, dose-escalation, U.S. Phase I trial to evaluate 10, 20, 30, 40, 50 and 62.5 mg/m 2 IV CBL0137 given on days 1, 8 and 15 of a...